tbuckley/cabot-search huggingface dataset:
NIMG-21. IMPACT OF GENETIC ALTERATIONS ON TUMOR LOCATIONS AND LESION HETEROGENEITY FOR WHO GRADE 2 AND 3 GLIOMAS: A VOXEL-BASED LESION MAPPING AND IMAGE TEXTURE ANALYSIS OF 201 GLIOMAS
Authors: Manabu Kinoshita, Hideyuki Arita, Toshiki Yoshimine, Masamichi Takahashi, Yoshitaka Narita, Yuzo Terakawa, Naohiro Tsuyuguchi, Yoshiko Okita, Masahiro Nonaka, Shusuke Moriuchi, Junya Fukai, Shuichi Izumoto, Kenichi Ishibashi, Yoshikazu Nakajima, Masatoshi Takagaki, Tomoko Shofuda, Yoshinori Kodama, Kanji Mori, Koichi Ichimura, Yonehiro Kanemura
Journal: Neuro-Oncology (2016)

Genetic alterations found in WHO grade 2 and 3 gliomas include IDH1/2 and TERT promoter mutations and 1p19q co-deletion, which alterations are known to have great impact on the prognosis of the patient. In this research, the authors attempted to test the hypothesis that genetic alterations could contribute to the locations and heterogeneity of the tumor by analyzing 201 WHO grade 2 and 3 gliomas using voxel-based lesion mapping (VLM) and image texture analysis. All T2-hyperintese lesions were normalized and mapped on the standard MRI atlas (MNI152) using normalized mutual information algorithm. In addition, image texture, that is the heterogeneity of the lesion on T2-weighted images, were evaluated by calculating the entropy of the lesion. Higher entropy is known to correspond to more heterogenous texture of the image and vice versa. 201 cases were divided into 3 groups according to the genetic alterations; 67 cases for IDH1/2 and TERT promoter mutated (IDHmt/TERTmt), 61 cases for IDH1/2 mutated but TERT promoter wild-type (IDHmt/TERTwt) and 73 cases for IDH1/2 wild-type gliomas (IDHwt). VLM revealed that IDHmt tumors tended to reside involving the cortex of the brain involving frontal, insular and temporal cortexes, while IDHwt tumors located closer to the center of the brain. IDHmt/TERTmt tumors were found to involve the frontal lobe 18% more than IDHmt/TERTwt tumors, while the temporal lobe being 20% less. Image texture analysis showed that entropies of T2-hyperintese lesions were 6.31 ± 0.47, 6.39 ± 0.42 and 6.05 ± 0.54 respectively for IDHmt/TERTmt, IDHmt/TERTwt and IDHwt tumors with IDHwt tumors being statistically significantly lower than the other two types of tumors (one-way ANOVA and Tukey’s Comparison Test). These results confirm that genetic alterations of glioma do affect locations and heterogeneity of the lesion.
Preclinical Development of FLT3-Redirected Chimeric Antigen Receptor T Cell Immunotherapy for Acute Myeloid Leukemia
Authors: Christopher Daniel Chien, Christopher Tor Sauter, Kazusa Ishii, Sang Minh Nguyen, Feng Shen, Sarah K Tasian, Weizao Chen, Dimiter S Dimitrov, Terry J Fry
Journal: Blood (2016)
Juxtaposition of the HPFH2 Enhancer Is Not Sufficient To Reactivate the g-Globin Gene in Adult Erythropoiesis in bYAC Transgenic Mice.
Authors: Ping Xiang, Xin Ye, Hemei Han, Mary Stafford, Stamatoyannopoulos George, Qiliang Li
Journal: Blood (2004)
Atheroprotective Effects and Molecular Targets of Tanshinones Derived From Herbal Medicine Danshen
Authors: Jian Fang, Peter J. Little, Suowen Xu
Journal: Medicinal Research Reviews (2017)

Abstract Medicinal plant‐derived bioactive compounds modulate multiple therapeutic targets in cardiovascular diseases (CVDs), rendering herb‐derived phytochemicals effective against one of the major CVDs‐atherosclerosis. Danshen ( Salvia milthiorriza Bunge) is a Chinese medicine that has been used in cardio‐ and cerebro‐vascular therapeutic remedies in Asian countries for many years. Emerging evidence from cellular, animal, and clinical studies suggests that major lipophilic tanshinones from Danshen can treat atherosclerotic CVDs. In this review, we highlight recent advances in understanding the molecular mechanisms of tanshinones in treating atherosclerosis, ranging from endothelial dysfunction to chronic inflammation. We also overview new molecular targets of tanshinones, including endothelial nitric oxide synthase, AMP‐activated protein kinase, ABC transporter A1, heme oxygenase 1, soluble epoxide hydrolase, 11β‐hydroxysteroid dehydrogenase, estrogen receptor, and proprotein convertase subtilisin/kexin type 9. Thus, this review provides a new perspective for advancing our understanding of the “ancient” herb Danshen from “modern” biomedical perspectives, supporting the possibility of exploiting tanshinones and derivatives as effective therapeutics against atherosclerosis‐related cardiovascular and metabolic diseases.
Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel/cisplatin/S-1 as neoadjuvant chemotherapy for locally advanced gastric cancer
Authors: T. Aoyama, K. Nishikawa, K. Fujitani, K. Tanabe, S. Ito, T. Matsui, A. Miki, H. Nemoto, K. Sakamaki, T. Fukunaga, Y. Kimura, N. Hirabayashi, T. Yoshikawa
Journal: Annals of Oncology (2017)
Evaluation of breast cancer patients with genetic risk: Before and after a multidisciplinary heredofamiliar cancer unit implementation
Authors: M. Lobo, S. Lopez-Tarruella, S. Luque, S. Lizarraga, P. Rincon, A. Hernandez, E. Mendizabal, O. Bueno, M. Cebollero, S. Perez Ramirez, Y. Jerez, M.I. Palomero Plaza, R. Gonzalez del Val, G. Garcia, I. Echavarria Diaz-Guardamino, A. Calin, J.A. Blanco, C. Flores Sanchez, M. Martin, I. Marquez-Rodas
Journal: Annals of Oncology (2016)
Effects of Oprozomib in Combination with Pomalidomide and/or Dexamethasone on Human Multiple Myeloma Tumors Growing in SCID Mice
Authors: Eric Sanchez, Mingjie Li, Abigail Gillespie, Puja Mehta, Suzie Vardanyan, Gigi Garzio, George Tang, Cathy Wang, Haiming Chen, James R Berenson@imbcr.org
Journal: Blood (2015)
IMST-55. LYMPH NODE AND URINE METABOLOMICS: A NON-INVASIVE STRATEGY TO PREDICT EFFICACY OF DENDRITIC CELL VACCINE IMMUNOTHERAPY
Authors: Hassan Azari, Farhad Dastmalchi, James R Rocca, Huadong Zeng, Aida Karachi, Duane Mitchell, Maryam Rahman
Journal: Neuro-Oncology (2016)

We recently demonstrated that robust migration of DCs to the draining lymph nodes was essential for survival benefit in GBM patients receiving DC vaccines. In this study we evaluated the early phase of immune-activation in lymph nodes and the subsequent metabolic changes in the urine to predict the outcome of DC based immunotherapy. DCs were generated from the bone marrow of adult mice. DCs were harvested, electroporated with OVA mRNA and used to vaccinate mice that received OT-1 splenocytes. After vaccination, the animals underwent lymph node and bladder magnetic resonance imaging (MRI) spectroscopy and had collection of urine and draining lymph nodes for nuclear magnetic resonance (NMR) spectroscopy analysis and flow cytometry. Lymphocytes from vaccinated animals demonstrated an increase in alpha ketoglutarate and lactate by flow cytometry. A more in depth metabolic analysis was performed of these cells using NMR spectroscopy that demonstrated an overall increase in all metabolic spectral signals correlating with an increase in lymphocytes in vaccinated lymph nodes. MRI spectroscopy demonstrated changes in fat signals in the vaccinated lymph nodes compared to control lymph nodes but no significant metabolic differences. In contrast, the bladder of DC vaccinated animals showed unique MRI spectral signatures that were not observed in control animals including increases in urea, taurine, creatinine, and citrate. Furthermore, specific signals were detected in urine NMR spectra of the DC vaccinated animals that were absent in control animals. Urine NMR and MRI spectroscopy are feasible and demonstrate metabolic changes induced by vaccine initiated immune response. Further experiments are needed to establish these findings as biomarkers for vaccine functionality.
Start (active surveillance or radical treatment for newly diagnosed patients with a localized, low risk, prostate cancer): an epidemiological study of the Oncology Network of Piemonte and Valle d’Aosta. Update 2017
Authors: C. Galassi, M. Ceccarelli, C. Monagheddu, E. Pagano, R. Rosato, P. Ivaldi, E. Bollito, A. Zitella, S. De Luca, M. Camilli, F. Munoz, A.R. Bellissimo, F. Bongiovanni, F. Ponti di Sant'Angelo, M. Mistrangelo, G. Ciccone, O. Bertetto
Journal: Annals of Oncology (2017)
Sustained Functional T Cell Persistence and B Cell Aplasia Following CD19-Targeting Adoptive T Cell Immunotherapy for Relapsed, Refractory CD19+ Malignacy
Authors: Michael Kalos, Bruce L. Levine, Timothy L Macatee, Irina Kulikovskaya, Erica Suppa, Bipulendu Jena, Saar I. Gill, Laurence J N Cooper, Stephan A. Grupp, David L Porter, Carl H. June
Journal: Blood (2012)
Imatinib Alone (IA) Vs. Imatinib + Ara-C (IMAC): A Randomized Phase III Clinical Trial for the Treatment of Early Phase (EP) Chronic Myeloid Leukemia (CML) Ph+. Preliminary Report of Mexican Cooperative Leukemia Group (GRUMELA).
Authors: Rafael Hurtado Monroy, Pablo Vargas-Viveros, Eduardo Cervera, Myrna Candelaria, Alvaro Aguayo, Emma Gallardo, Eucario Leon, Juan Labardini, Ricardo Sosa, Rogelio Paredes, Fernando Romero, Oscar Perez, Omar Coronel-Ayala
Journal: Blood (2004)
Do the Data on Scalp Cooling for Patients With Breast Cancer Warrant Broad Adoption?
Authors: Howard (Jack) West
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Conditioning Immune and Endocrine Parameters in Humans: A Systematic Review
Authors: Judith Tekampe, Henriët van Middendorp, Stefanie H. Meeuwis, Jelle W.R. van Leusden, Gustavo Pacheco-López, Ad R.M.M. Hermus, Andrea W.M. Evers
Journal: Psychotherapy and Psychosomatics (2017)

&lt;b&gt;&lt;i&gt;Background:&lt;/i&gt;&lt;/b&gt; Conditioned pharmacological effects may provide relevant clinical opportunities to improve treatment for patients with a variety of conditions. The aim of this systematic review was to create an overview of studies in this field of research and to investigate whether specific characteristics of the study design make for successful conditioning. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; The protocol of this review was registered in Prospero (PROSPERO 2015: CRD42015024148). A systematic literature search was conducted in the databases PubMed, Embase, and PsychInfo. Studies were included if they were placebo-controlled trials in humans in which the effects of a pharmacological agent on immune or endocrine outcomes (e.g., interleukin-2 and cortisol) were conditioned, using a specific conditioned stimulus. The risk of bias of each study was assessed using the Cochrane risk-of-bias tool. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; The final selection included 16 studies. Overall, those studies indicate that conditioning of immunosuppression, conditioning of allergic responses, and conditioning of insulin and glycemic responses is possible. Regarding immunostimulants, antiallergic effects, and cortisol conditioning, the preliminary results are promising, but additional studies are needed. &lt;b&gt;&lt;i&gt;Conclusions:&lt;/i&gt;&lt;/b&gt; This systematic review shows classical conditioning of immune and endocrine responses for various pharmaceutical substances. The studies reviewed here indicate that the number of acquisition and evocation sessions, and characteristics of the unconditioned and conditioned stimuli, are important determinants of the effectiveness of pharmacological conditioning on immune and endocrine parameters. In the future, conditioned pharmacological effects may be used clinically as adjunct therapy in various patient populations.
Functionalized Polymeric Membrane with Enhanced Mechanical and Biological Properties to Control the Degradation of Magnesium Alloy
Authors: Hoi Man Wong, Ying Zhao, Frankie K. L. Leung, Tingfei Xi, Zhixiong Zhang, Yufeng Zheng, Shuilin Wu, Keith D. K. Luk, Kenneth M. C. Cheung, Paul K. Chu, Kelvin W. K. Yeung
Journal: Advanced Healthcare Materials (2017)

To achieve enhanced biological response and controlled degradation of magnesium alloy, a modified biodegradable polymer coating called polycaprolactone (PCL) is fabricated by a thermal approach in which the heat treatment neither alters the chemical composition of the PCL membrane nor the rate of magnesium ion release, pH value, or weight loss, compared with the untreated sample. The changes in the crystallinity, hydrophilicity, and oxygen content of heat-treated PCL coating not only improve the mechanical adhesion strength between the coating and magnesium substrate but also enhance the biological properties. Moreover, the thermally modified sample can lead to higher spreading and elongation of osteoblasts, due to the enhanced hydrophilicity and CO to CO functional group ratio. In the analyses of microcomputed tomography from one to four weeks postoperation, the total volume of new bone formation on the heat-treated sample is 10%-35% and 70%-90% higher than that of the untreated and uncoated controls, respectively. Surprisingly, the indentation modulus of the newly formed bone adjacent to the heat-treated sample is ≈20% higher than that of both controls. These promising results reveal the clinical potential of the modified PCL coating on magnesium alloy in orthopedic applications.
<i>Notes from the Field:</i> Ongoing Cholera Epidemic — Tanzania, 2015–2016
Authors: Rupa Narra, Justin M. Maeda, Herilinda Temba, Janneth Mghamba, Ali Nyanga, Ashley L. Greiner, Muhammad Bakari, Karlyn D. Beer, Sae-Rom Chae, Kathryn G. Curran, Rachel B. Eidex, James J. Gibson, Thomas Handzel, Stephen J. Kiberiti, Rogath S. Kishimba, Haji Lukupulo, Theophil Malibiche, Khalid Massa, Amani E. Massay, Lindsey S. McCrickard, Geofrey J. Mchau, Vida Mmbaga, Ahmed A. Mohamed, Elibariki R. Mwakapeje, Emmanuel Nestory, Anna E. Newton, Elvis Oyugi, Anu Rajasingham, Michelle E. Roland, Neema Rusibamayila, Senga Sembuche, Loveness J. Urio, Tiffany A. Walker, Alice Wang, Robert E. Quick
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

On August 15, 2015, the Tanzanian Ministry of Health, Community Development, Gender, Elderly and Children (MOHCDGEC) was notified about a case of acute watery diarrhea with severe dehydration in a patient in Dar es Salaam.Vibrio cholerae O1, biotype El tor, serotype Ogawa, was isolated from the patient's stool and an investigation was initiated.MOHCDGEC defined a suspected cholera case as the occurrence of severe dehydration or death from acute watery diarrhea in a person aged ≥5 years, or acute, profuse watery diarrhea with or without vomiting in a person aged ≥2 years in a region with an active cholera outbreak.A confirmed cholera case was defined as isolation of V. cholerae O1 from the stool of a person with suspected cholera.Tanzania's first reported cholera epidemic was in 1974 with intermittent outbreaks since then; the largest epidemic occurred in 1997, with 40,249 cases and 2,231 deaths (case fatality rate [CFR] was 5.5%) (1).As of November 26, 2016, the current epidemic continues, affecting 23 (92%) of 25 regions in mainland Tanzania (excluding the Zanzibar archipelago), with a cumulative reported case count of 23,258 and a cumulative CFR of 1.5%.The median number of reported cholera cases per week was 271 (range = 5-1,240) (Figure).Approximately half of all reported cases have been from four regions: Dar es Salaam (5,104; 22%), Morogoro (3,177; 14%), Mwanza (2,311; 10%), and Mara (2,299; 10%).Of 511 stool specimens tested during August 17, 2015-March 18, 2016 at the National Health Laboratory-Quality Assurance Training Center in Dar es Salaam, 268 (52%) were positive for V. cholerae; all specimens were serogroup O1, biotype El tor, serotype Ogawa.Antimicrobial resistance (AMR) testing revealed sensitivity to cotrimoxazole, ceftriaxone, tetracycline, ciprofloxacin, and chloramphenicol, and resistance to nalidixic acid and ampicillin.* These authors contributed equally to this report.* Suspected cholera (severe dehydration or death from acute watery diarrhea in a person aged ≥5 years, or acute, profuse watery diarrhea with or without vomiting in a person aged ≥2 years in a region with an active cholera outbreak) and confirmed cases (isolation of V. cholerae O1 from the stool of a person with suspected cholera).† Excluding the Zanzibar archipelago.
Correlates of Prenatal and Early-Life Tobacco Smoke Exposure and Frequency of Common Gene Deletions in Childhood Acute Lymphoblastic Leukemia
Authors: Adam J. de Smith, Maneet Kaur, Semira Gonseth, Alyson Endicott, Steve Selvin, Luoping Zhang, Ritu Roy, Xiaorong Shao, Helen M. Hansen, Alice Y. Kang, Kyle M. Walsh, Gary V. Dahl, Roberta McKean-Cowdin, Catherine Metayer, Joseph L. Wiemels
Journal: Cancer Research (2017)

Tobacco smoke exposure has been associated with risk of childhood acute lymphoblastic leukemia (ALL). Understanding the relationship between tobacco exposures and specific mutations may yield etiologic insights. We carried out a case-only analysis to explore whether prenatal and early-life tobacco smoke exposure influences the formation of leukemogenic genomic deletions. Somatic copy number of 8 genes frequently deleted in ALL (CDKN2A, ETV6, IKZF1, PAX5, RB1, BTG1, PAR1 region, and EBF1) was assessed in 559 pretreatment tumor samples from the California Childhood Leukemia Study. Parent and child's passive tobacco exposure was assessed using interview-assisted questionnaires as well as DNA methylation in aryl-hydrocarbon receptor repressor (AHRR), a sentinel epigenetic biomarker of exposure to maternal smoking during pregnancy. Multivariable Poisson regressions were used to test the association between the smoking exposures and total number of deletions. Deletion burden varied by subtype, with a lower frequency in high-hyperdiploid and higher frequency in ETV6-RUNX1 fusion ALL. The total number of deletions per case was positively associated with tobacco smoke exposure, in particular for maternal ever-smoking (ratio of means, RM, 1.31; 95% CI, 1.08-1.59), maternal smoking during pregnancy (RM, 1.48; 95% CI, 1.12-1.94), and during breastfeeding (RM, 2.11; 95% CI, 1.48-3.02). The magnitude of association with maternal ever-smoking was stronger in male children compared with females (Pinteraction = 0.04). The total number of deletions was also associated with DNA methylation at the AHRR epigenetic biomarker (RM, 1.32; 95% CI, 1.02-1.69). Our results suggest that prenatal and early-life tobacco smoke exposure increase the frequency of somatic deletions in children who develop ALL. Cancer Res; 77(7); 1674-83. ©2017 AACR.
Defects in Primary Hemostasis and Acquired Von Willebrand Disease As Cause of Bleeding in Patients with Multiple Myeloma
Authors: Clemens Hinterleitner, Klaus Peter Kreisselmeier, Ann Christin Pecher, Katja C. Weisel, Lothar Kanz, Hans Georg Kopp, Karl G. Jaschonek
Journal: Blood (2015)
QLIF-14. QUALITY IMPROVEMENT AND PRACTICE BASED RESEARCH IN NEURO-ONCOLOGY USING THE ELECTRONIC MEDICAL RECORD
Authors: Ryan Merrell, Nina Martinez, Susan Stasinos, James Muresan, Shaun Walters, Laura Amelse, Inna Glatman, Magdalena Dudek, Vimal Patel, Roberta Frigerio, Demetrius Maraganore
Journal: Neuro-Oncology (2016)

1) to develop a structured clinical documentation support (SCDS) toolkit within the electronic medical record (EMR) that navigates care, writes notes, and captures data at office visits; 2) To share the toolkit with Neuro-oncologists using the Epic EMR platform, as part of a Neurology Practice Based Research Network (NPBRN). We developed a seven-stage process for quality improvement and practice based research in Neurology using the EMR: 1) SCDS toolkits (custom navigators, electronic forms, smart data elements); 2) enrollment reports; 3) data quality reports; 4) descriptive cohort reports; 5) quality improvement dashboards; 6) clinical decision support; 7) sharing of toolkits and data (NPBRN). We enrolled subjects in a germline DNA biobank. We met every two weeks for three months to develop content: define the cohort, select outcome measures, delineate factors known to modify disease progression. We assigned tasks to the care team, and mapped data elements to the progress note. We then met every two weeks for three more months with programmer analysts to build and test the SCDS toolkit. Autoscored and interpreted tests included the Generalized Anxiety Disorder 7-item, Center for Epidemiological Studies Depression, Karnofsky Performance Scale, MD Anderson Symptom Inventory, and Short Test of Mental Status. Our toolkit captures ~800 fields of data per office visit. We have used the toolkits ~200 times to assess brain tumor patients (initially, six monthly if malignant, annually if benign). We have enrolled 129 brain tumor patients in our biobank: 53 “benign”, 36 “malignant primary”, and 40 “metastatic”. We will present screenshots of our SCDS toolkit, descriptive data, and pairwise correlations and principle component analyses for score test measures. The EMR can be effectively structured to standardize Neuro-oncology office visits, capture data, and support multicenter quality improvement and practice based research initiatives.
Budget impact analysis of the 21-gene assay (Oncotype DX® breast cancer) for the breast cancer treatment in the Basque country
Authors: M.G. Toribio, J. Mar, E. Galve, I. Alvarez, A. Lahuerta, G. Unanue, O. Ibarrondo, P. Novas, N. Ancizar, L. Larburu, M. Hidalgo, J.F. Arango, C. Churruca, A. Plazaola, I. Perez, P. Purificación Martínez del Prado, S. Dominguez, A. Paisan
Journal: Annals of Oncology (2016)
Recombinant Human Thrombomodulin in the Treatment of Acute Myeloid Leukemia Patients Complicated by Disseminated Intravascular Coagulation: Retrospective Analysis of the Outcomes Between the Patients with Heparin and with Recombinant Human Thrombomodulin Therapy
Authors: Naoki Takezako, Naohiro Sekiguchi, Akihisa Nagata, Satoshi Noto, Akiyoshi Miwa
Journal: Blood (2011)
Margaret McCartney: General practice is a long game
Authors: Margaret McCartney
Journal: BMJ (2017)

At the end of another long and difficult day, it’s easy to lose all sense of the joy of working as a GP. It’s still there, under a pile of paperwork maybe, but it’s still there.

I’m thinking about the baby born after many years of trying, when you exchange smiles with the parents, who know too well the years of tears and infertility.

I’m thinking about the bereaved husband, and the wife who came to talk to you about her fears around …
Older Patients with Hodgkin Lymphoma (HL) Undergoing Autologous Stem Cell Transplantation for Relapsed/Refractory Disease Have Inferior Survival Compared to Younger Patients
Authors: Akshay Sharma, Minghui Duan, Michael Graiser, Hongzheng Zhang, Amelia Langston, Sagar Lonial, Christopher R Flowers, Ann Haight, Edmund K Waller
Journal: Blood (2011)
Prognostic role for derived neutrophil-to-lymphocyte ratio in early breast cancer
Authors: A. Ocana Fernandez, A.J. Templeton, M. Casas, M. Sánchez-Aragó, R. Caballero, A. Rodríguez Lescure, A. Ruiz, E. Alba, L. Calvo, M. Ruiz, A. Santaballa, C. Rodríguez, C. Crespo, M. Ramos, J.M. Gracia Marco, A. Lluch-Hernandez, I. Alvarez, E. Carrasco, E. Amir, M. Martin
Journal: Annals of Oncology (2016)